We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
Abbott (ABT - Free Report) closed the most recent trading day at $85.68, moving -1.14% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.02%. At the same time, the Dow added 0.36%, and the tech-heavy Nasdaq gained 0.07%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 7.66% lagged the Medical sector's gain of 2.02% and the S&P 500's gain of 5.12%.
The investment community will be closely monitoring the performance of Abbott in its forthcoming earnings report. The company is predicted to post an EPS of $1.28, indicating a 1.59% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $12.53 billion, reflecting a 12.43% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.48 per share and revenue of $50.49 billion, indicating changes of +6.41% and +13.9%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.42% lower. Abbott is currently sporting a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Abbott has a Forward P/E ratio of 15.82 right now. This valuation marks a discount compared to its industry average Forward P/E of 18.69.
We can also see that ABT currently has a PEG ratio of 1.45. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. ABT's industry had an average PEG ratio of 1.5 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 160, placing it within the bottom 35% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
Abbott (ABT - Free Report) closed the most recent trading day at $85.68, moving -1.14% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.02%. At the same time, the Dow added 0.36%, and the tech-heavy Nasdaq gained 0.07%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 7.66% lagged the Medical sector's gain of 2.02% and the S&P 500's gain of 5.12%.
The investment community will be closely monitoring the performance of Abbott in its forthcoming earnings report. The company is predicted to post an EPS of $1.28, indicating a 1.59% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $12.53 billion, reflecting a 12.43% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.48 per share and revenue of $50.49 billion, indicating changes of +6.41% and +13.9%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.42% lower. Abbott is currently sporting a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Abbott has a Forward P/E ratio of 15.82 right now. This valuation marks a discount compared to its industry average Forward P/E of 18.69.
We can also see that ABT currently has a PEG ratio of 1.45. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. ABT's industry had an average PEG ratio of 1.5 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 160, placing it within the bottom 35% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.